Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Haijun Yu

Showing results (261-270 of 303) with videos related to

Pageof 31
Sort By:
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|March 28, 2023
Optimal treatment strategy and prognostic analysis for hypopharyngeal squamous-cell carcinoma patients with T3-T4 or node-positive: A population-based studyLinhui Zheng, Sha Fang, Linfeng Ye, et al.
Biomaterials|February 22, 2015
Inhibition of metastasis and growth of breast cancer by pH-sensitive poly (β-amino ester) nanoparticles co-delivering two siRNA and paclitaxelShan Tang, Qi Yin, Jinghan Su, et al.
Nature Communications|June 18, 2026
POLY-Senolytic nanoplatform for tumor-specific eradication of senescent tumor cells and mitigation of radiotherapy-induced immune resistance of cancerYi Lai, Shunan Zhang, Jiaxing Pan, et al.
Science Advances|November 15, 2024
Tumor-specific delivery of clickable inhibitor for PD-L1 degradation and mitigating resistance of radioimmunotherapyBo Hou, Jiayi Ye, Lujia Huang, et al.
Oncology Reports|February 28, 2013
Concomitant overexpression of EGFR and CXCR4 is associated with worse prognosis in a new molecular subtype of non-small cell lung cancerAlya A Al Zobair, Barrak F Al Obeidy, Lei Yang, et al.
Cell Death & Disease|June 5, 2026
The CDK4/6 inhibitor dalpiciclib augments the antitumor efficacy of enzalutamide in preclinical models of castration-resistant prostate cancer through inhibition of MCM4-mediated DNA replicationYue Liu, Yuan Ke, Jingtian Yu, et al.
Nature Communications|July 26, 2022
Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapyJing Gao, Bo Hou, Qiwen Zhu, et al.
Nature Communications|August 4, 2024
A region-confined PROTAC nanoplatform for spatiotemporally tunable protein degradation and enhanced cancer therapyJing Gao, Xingyu Jiang, Shumin Lei, et al.
Angewandte Chemie (International Ed. in English)|May 29, 2020
Size-Mediated Recurring Spinel Sub-nanodomains in Li- and Mn-Rich Layered Cathode MaterialsBiwei Xiao, Hanshuo Liu, Ning Chen, et al.
Nature Communications|August 25, 2022
Author Correction: Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapyJing Gao, Bo Hou, Qiwen Zhu, et al.
Pageof 31

Showing results (261-270 of 303) with videos related to

Sort By:
Pageof 31
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|March 28, 2023
Optimal treatment strategy and prognostic analysis for hypopharyngeal squamous-cell carcinoma patients with T3-T4 or node-positive: A population-based studyLinhui Zheng, Sha Fang, Linfeng Ye, et al.
Biomaterials|February 22, 2015
Inhibition of metastasis and growth of breast cancer by pH-sensitive poly (β-amino ester) nanoparticles co-delivering two siRNA and paclitaxelShan Tang, Qi Yin, Jinghan Su, et al.
Nature Communications|June 18, 2026
POLY-Senolytic nanoplatform for tumor-specific eradication of senescent tumor cells and mitigation of radiotherapy-induced immune resistance of cancerYi Lai, Shunan Zhang, Jiaxing Pan, et al.
Science Advances|November 15, 2024
Tumor-specific delivery of clickable inhibitor for PD-L1 degradation and mitigating resistance of radioimmunotherapyBo Hou, Jiayi Ye, Lujia Huang, et al.
Oncology Reports|February 28, 2013
Concomitant overexpression of EGFR and CXCR4 is associated with worse prognosis in a new molecular subtype of non-small cell lung cancerAlya A Al Zobair, Barrak F Al Obeidy, Lei Yang, et al.
Cell Death & Disease|June 5, 2026
The CDK4/6 inhibitor dalpiciclib augments the antitumor efficacy of enzalutamide in preclinical models of castration-resistant prostate cancer through inhibition of MCM4-mediated DNA replicationYue Liu, Yuan Ke, Jingtian Yu, et al.
Nature Communications|July 26, 2022
Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapyJing Gao, Bo Hou, Qiwen Zhu, et al.
Nature Communications|August 4, 2024
A region-confined PROTAC nanoplatform for spatiotemporally tunable protein degradation and enhanced cancer therapyJing Gao, Xingyu Jiang, Shumin Lei, et al.
Angewandte Chemie (International Ed. in English)|May 29, 2020
Size-Mediated Recurring Spinel Sub-nanodomains in Li- and Mn-Rich Layered Cathode MaterialsBiwei Xiao, Hanshuo Liu, Ning Chen, et al.
Nature Communications|August 25, 2022
Author Correction: Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapyJing Gao, Bo Hou, Qiwen Zhu, et al.
Pageof 31